Pegylated interferon with ribavirin in the treatment of chronic active hepatitis C in Egyptian patients: efficacy of response in a retrospective study

Chronic hepatitis C is one of the major causes of cirrhosis, hepatocellular carcinoma and considered the main indication for liver transplantation. In Egypt, high HCV rates were reported among several population groups reaching up to 20%. Interferon Alfa is the current therapy forchronic hepatitis C .Yet, combination therapy of Alfa interferon and ribavirin is more effective than interferon alone in increasing the response rates. Aim of work is to study efficacy of response in Egyptian patients with chronic active hepatitis C who had received pegylated interferon plus ribavirin as regarding the biochemical and virologic response. The results of this study showed that patients received Pegylated interferon alfa-2a plus ribavirin had significant improvement in serum ALT levels in around 71% of them. Also 58.94%of these patients achieved sustained clearance of the virus six months after stopping treatment. The combination therapy of Pegylated interferon alfa and ribavirin is effective in achieving biochemical and virological responses and is highly recommended as an initial therapy for patients with chronic hepatitis C

comparative study of anxiety and depression symptoms among sewermen

This comparative study was done on a group of sewermen, and a control group of municipal of the same socio-demographic characteristics. The aim was to test hypothesis that they were different in the frequency, and or intensity of anxiety and depression symptoms. These were measured through using Zung scale. The results show that sewermen had lower anxiety scores than control group, and the different was statistically significant. No significant differences were observed in relation to depression symptoms